News and Events
Cerebral Therapeutics Names Julie Foster as Chief Operating Officer
Strategic Appointment to Guide Business Operations, Growth and Portfolio Scalability
January 25, 2023 04:05 PM Eastern Standard Time
AURORA, Colo.--(BUSINESS WIRE)--Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today the appointment of MedTech industry veteran Julie Foster as Chief Operating Officer. Julie succeeds John Foster who served as Cerebral Therapeutic’s President and COO since 2019, who will move into a business advisor role for the company.
Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing
AURORA, Colo.--(BUSINESS WIRE)--Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today $40 million in Series C funding led by Lynx1 Capital Management with participation from existing investors RA Capital Management, Perceptive Advisors, Vivo Capital LLC, and Granite Point Capital Management L.P. In conjunction with the financing round, Weston Nichols, Ph.D., Managing Partner of Lynx1 Capital Management and Tim Scannell, former President and COO of Stryker, will join the Board of Directors.
AURORA, Colo.--(BUSINESS WIRE)--Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today $40 million in Series C funding led by Lynx1 Capital Management with participation from existing investors RA Capital Management, Perceptive Advisors, Vivo Capital LLC, and Granite Point Capital Management L.P.
Cerebral Therapeutics, Inc. Names Guy Anthony as Chief Financial Officer
AURORA, Colo.--(BUSINESS WIRE)--Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative treatments for neurological disease, has appointed Guy Anthony as Chief Financial Officer.
Hope grows for epilepsy patients as clinical trial enters next phase
Phase 2B of the trial is now currently underway and builds on the promising results of earlier testing.
Prof Cook describes it as a very exciting stage that allows them to extend the treatment to much larger groups.
Read the full article on the Saint Vincent's Melbourne website.
World-first epilepsy treatment to be rolled out to dozens more patients
It all begins with an idea.
Adam Daly was deemed untreatable.
Cerebral Therapeutics Announces Enrollment of First Patient in a Multicenter Randomized Controlled Phase 2b Trial in Epilepsy
It all begins with an idea.
AURORA, Colo.--(BUSINESS WIRE)--Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative treatments for neurological diseases, today announced that the first patient has been enrolled in a Phase 2b study of intracerebroventricular drug delivery of the anti-seizure medication CT-010 in patients with medically refractory epilepsy. The trial is enrolling adult epilepsy patients with temporal lobe onset, with or without secondary generalized seizures.
A clinical feasibility study at St. Vincent’s Hospital Melbourne (published in The Lancet - EClinicalMedicine) established for the first time that intracerebroventricular administration of sodium valproate is a potentially effective strategy in the treatment of refractory epilepsy. The study found that subjects experienced a mean 77 percent seizure reduction and extended periods of seizure freedom. All subjects reported significant quality of life improvement with minimal drug side effects. Based on these promising initial results, Cerebral Therapeutics has developed a propriety formulation, CT-010, and enhanced the infusion system for continued investigation of the safety and effectiveness of the therapy.
Cerebral Therapeutics Appoints Stephen J. Farr as Chairman and Welcomes Stephen D. Collins to the Board of Directors
It all begins with an idea.
AURORA, Colo.--(BUSINESS WIRE)--Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative treatments for neurological diseases, has appointed Stephen J. Farr, PhD as Chairman of the board of directors. Dr. Farr is the Co-Founder, President, and Chief Executive Officer of Zogenix, a biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
“Dr. Farr’s experience in CNS drug development and advanced drug delivery will provide valuable direction to Cerebral Therapeutics as it launches its Phase 2 trial of CT-010 for refractory epilepsy and builds out its pipeline of drugs for site specific administration to the CNS,” said Dan Abrams, M.D., Chief Executive Officer of Cerebral Therapeutics. “The company is grateful to Warren Lammert who served as the Board Chair during the company’s formative years and provided meaningful leadership for our growth. We also warmly welcome Dr. Stephen Collins to the board as he brings extensive CNS product development experience with a special focus on epilepsy.”
Cerebral Therapeutics Announces Publication of Phase 2a Clinical Trial Results
Cerebral Therapeutics publishes the first human study to test a long-term anti-seizure therapy through implantation of an intracerebroventricular drug delivery system for drug-resistant epilepsy
AURORA, Colo., June 1, 2020 - Cerebral Therapeutics, a clinical-stage pharmaceutical company developing innovative treatments for uncontrolled neurological diseases, announced today the publication in The Lancet - EClinicalMedicine of results from its Phase 2a clinical trial evaluating intracerebroventricular drug delivery of the anti-seizure medication sodium valproate in subjects with medically refractory epilepsy.
A Phase 2a clinical study was undertaken over the course of two and a half years at St. Vincent’s Hospital at The University of Melbourne in Australia evaluating the therapy in subjects with drug resistant focal seizures through use of an implantable infusion system to deliver a reformulation of the anti-seizure medication sodium valproate into the cerebrospinal fluid, bypassing the blood-brain barrier. In the study, five adult subjects who were refractory to oral valproate were treated with this therapy in order to evaluate the dose range of sodium valproate administered and to evaluate the safety and efficacy of this therapy. The study found that 80% of subjects were responders (> 50% seizure reduction), and three subjects experienced periods of complete seizure freedom. All five subjects reported significant quality of life improvements, with minimal drug side effects. The study demonstrated that intracerebroventricular administration of sodium valproate appears safe and well tolerated in subjects with medically refractory epilepsy over many months.
This is the first demonstration of chronic intracerebroventricular therapy as a potentially effective strategy in the treatment of medically resistant subjects. Despite the refractory nature of epilepsy in these subjects and the unsuccessful earlier use of oral valproate, this proprietary infusion therapy is safe, well tolerated, and holds promise as an effective therapy for refractory epilepsy. Safety and efficacy will be further explored in a Phase 2a extension study, as well as an upcoming Phase 2b randomized controlled study.
The article can be found: https://www.thelancet.com/pdfs/journals/eclinm/PIIS2589-5370(20)30070-5.pdf
Cerebral Therapeutics Completes $35 million Series B Financing
AURORA, Colo., Jan. 7, 2020 /PRNewswire/ -- Cerebral Therapeutics, a clinical-stage pharmaceutical company developing innovative treatments for uncontrolled neurological diseases, announced today a $35 million Series B financing led by RA Capital Management, with participation from additional new investor Perceptive Advisors and existing investors Vivo Capital, LLC and Granite Point Capital Management, L.P. Matthew Hammond, Ph.D. of RA Capital Management, and Weston Nichols, Ph.D. of Perceptive Advisors, will join the Board of Directors.
Cerebral Therapeutics™ Names John Foster as President and Chief Operating Officer
Cerebral Therapeutics™, Inc. (Cerebral), a clinical-stage pharmaceutical company developing specialty medications for uncontrolled neurological diseases, announced today the appointment of industry veteran John Foster as President and Chief Operating Officer. Mr. Foster will utilize his extensive executive management experience leading companies, developing products and navigating the FDA regulatory environment to expand the strategic breadth and depth of the Cerebral executive management team.
Cerebral Therapeutics™ to Present Clinical Data at Antiepileptic Drug and Device Trials XV Conference
Cerebral Therapeutics™, a clinical-stage pharmaceutical company developing specialty medications for uncontrolled neurological diseases, announced today that the Company will present at the Antiepileptic Drug and Device (AEDD) Trials XV conference, which is held every two years and is sponsored by The Epilepsy Study Consortium in collaboration with the University of Pennsylvania and the Epilepsy Foundation.
Cerebral Therapeutics™ Strengthens Clinical Development Leadership with Strategic Appointments
Lisa Shafer, Ph.D., Chief Scientific Officer, and Eric Distad, Vice President of Clinical Development, add Extensive CNS Drug-Device Development Experience
First clinical trial of reformulated epileptic drug to treat medically refractory epilepsy
A currently approved epileptic drug to treat seizures has been modified by a University of Colorado Anschutz Medical Campus professor and is currently being used in a clinical trial in Australia for medically refractory epilepsy.
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS, April 3, 2019
Cerebral Therapeutics™ Raises Series A Extension Financing to Advance Clinical-Stage Drug Device Combination Therapy to Phase 3 Readiness for Adult Refractory Epilepsy
Financing Led by Granite Point Capital and Vivo Capital
Cerebral Therapeutics™ Prepares IND and Clinical Development Program in the U.S.
Aurora, CO., March 8, 2019
Cerebral Therapeutics™ Raises Series A Financing to Advance Clinical-Stage Drug-Device Combination Therapy for Adult Refractory Epilepsy
Financing Led by Granite Point Capital and Vivo Capital
Cerebral Therapeutics™ Adds Three New Members to its Board of Directors
Aurora, CO., June 20, 2018